A Phase 2 Study of Efatutazone, an Oral PPAR Agonist, In Combination With Paclitaxel in Patients With Advanced Anaplastic Thyroid Cancer

What is the purpose of this trial?

This phase II trial studies how well inolitazone dihydrochloride (efatutazone dihydrochloride) and paclitaxel work in treating patients with anaplastic thyroid cancer that has spread to other places in the body and usually cannot be cured or controlled with treatment (advanced). Drugs used in chemotherapy, such as efatutazone dihydrochloride and paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading.



Alliance Cooperative Group

Start Date: 11/22/2016

End Date: 10/01/2017

Last Updated: 02/22/2018

Study HIC#: 1511016862

Get Involved

For more information about this study, contact:
Matthew Piscatelli
+1 203-737-8367
matthew.piscatelli@yale.edu

Investigators

Hari Anant Deshpande

Principal Investigator

Sub-Investigators